Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fat To Water: Big Hopes For Microbiome Approaches To Obesity and Metabolic Disease

This article was originally published in RPM Report

Executive Summary

Finding the right microbial balance in the gut may be the way of the future for treatment of conditions like obesity and diabetes. That’s where some notable medical futurists are looking and where some early commercial clinical trials are underway. In addition to all the usual uncertainties about new ideas in therapeutics, this idea has an extra question mark: what will the regulatory model be?

You may also be interested in...



In Brief: FDA responds to Nasacort suit, acts on acetaminophen and continues medical food enforcement

FDA responds to Nasacort Allergy suit; FDA will act on lower acetaminophen dose; FDA warns consumers about wart removers; FDA continues medical food enforcement; Supplements must include declared ingredients; CHPA applauds DXM-related legislation; and USP opens Shanghai facility.

Second Genome Scores A Deal With Janssen, A First In The Field Of Microbiome Therapeutics

Second Genome’s ulcerative colitis research alliance with Janssen Biotech is a first in the burgeoning microbiome therapeutics space, which may be transitioning from venture investment to commercial partnering. But is the deal an inflection point or a fluke?

NuMe Health Inc.

NuMe Health Inc. aims to market mixtures of edible substances that will act as "prebiotics" to shift ratios of certain bacteria in the lower intestine. The start-up intends to educate consumers about how "managing the microbiome" with products that are not drugs can positively affect metabolic health. First up: a mixture NuMe expects will improve biomarkers associated with pre-diabetes.

Topics

Related Companies

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel